StockData

Moleculin Biotech vs Transcode Therapeutics

MBRX and RNAZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MBRX and RNAZ compare

Moleculin Biotech is the larger company, worth 102 times as much as Transcode Therapeutics ($139M against $1.4M).

Transcode Therapeutics scores higher on the StockData Score (5 against 4 for Moleculin Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMBRXRNAZ
Size and price
Market cap$139M$1.4M
Share price$7.14$1.35
Change, 1 year−96.9%−84.0%
Change, 5 years−100.0%−100.0%
Beta (5Y)−1.160.63
Employees150K12
StockData Score
Total score45 (better)
Valuation score00
Growth score00
Performance score00
Health score45 (better)
Dividend score00
Valuation
P/B12.0×–
Profitability
Return on equity−524%–
Financial health
Debt / equity0.00–
Current ratio0.941.97 (better)
Altman Z-score−10.81−2.01 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions0.05%3.3%
Held by insiders20.2%–
Short interest, % of float0.35%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.